Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of CK-0801 in patients with autoimmune diseases and inflammatory disorders

Next Previous
Trial Profile

A phase I trial of CK-0801 in patients with autoimmune diseases and inflammatory disorders

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 0801 (Primary)
  • Indications Aplastic anaemia; Autoimmune disorders; Bone marrow disorders; Inflammation; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Cellenkos

    • Most Recent Events

    • 10 Jun 2018 According to a Cellenkos Inc. media release,the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application which allows for Cellenkosto proceed with a phase I clinical trial of CK0801
    • 10 Jun 2018 According to a Cellenkos Inc. media release, the company plans to initiate this trial in in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas
    • 07 Feb 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top